Compare Novo Nordisk A/S (NVO) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs New York Times Co — how do they compare? Novo Nordisk A/S trades at $38.45 (market cap $165.31B), while New York Times Co trades at $65.42 (market cap $10.74B). The key difference: Novo Nordisk A/S is far larger — about 15.4× New York Times Co's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals.
| NVO | NYT | |
|---|---|---|
Market Cap | $165.31B | $10.74B |
Volume | 11,432,838 | 2,096,352 |
Sector | Health | Media |
52-Week High | $63.98 | $85.86 |
52-Week Low | $35.29 | $54.66 |
Enterprise Value | $179.56B | $10.14B |
Dividend Yield | 4.71% | 1.38% |
Typical Hold Time | — | 81 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
The New York Times Company (NYSE: NYT) trades at $65.64, up 1.14% today, with a bullish technical signal and strong fundamentals. Revenue grew from $2.3B in 2022 to $2.8B in 2025, with net income margin expanding to 12.17%. Recent earnings beats and a declared $0.23 dividend highlight operational strength, though a shareholder lawsuit presents headline risk.
Outlook is positive given consistent earnings outperformance and analyst consensus target of $84.00, implying 28% upside. Key risks include the pending lawsuit's impact on reputation and competitive pressures in digital media. Cash flow generation remains robust, supporting dividend sustainability and growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
